Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Annals of Internal Medicine|May 8, 2020
Biomedical Research in Times of Emergency: Lessons From HistoryDeborah Doroshow, Scott Podolsky, Justin BarrJournal of the History of Medicine and Allied Sciences|December 15, 2018
New Directions in the Historiography of PsychiatryDeborah Doroshow, Matthew Gambino, Mical RazJournal of Cancer Metastasis and Treatment|June 19, 2024
The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomasMichael Offin, Bailey Fitzgerald, Marjorie G Zauderer, et al.Journal of the History of Medicine and Allied Sciences|November 18, 2025
Who Wins? Professional Identity and the American Association for the History of Medicine's Early Career Scholar AwardsJustin Barr, Deborah Doroshow, Todd Olszewski, et al.Cancer Treatment Reviews|May 22, 2024
Optimizing care in early phase cancer trials: The role of palliative careFionnuala Crowley, Richard Sheppard, Stephanie Lehrman, et al.Oncology and Therapy|November 9, 2025
Real-World Outcomes and Subsequent Treatment Patterns in Patients with Advanced Non-Small Cell Lung Cancer and Atypical EGFR Mutations Receiving First-Line Osimertinib MonotherapyJorge J Nieva, Xuejun Wang, Deborah Doroshow, et al.JCO Precision Oncology|September 16, 2021
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)Haider Mahdi, Navid Hafez, Deborah Doroshow, et al.Cancer|February 7, 2025
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trialMichael Cecchini, Mary Jo Pilat, Nataliya Uboha, et al.The Lancet. Gastroenterology & Hepatology|January 22, 2022
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trialThomas U Marron, Maria Isabel Fiel, Pauline Hamon, et al.Pageof 1